Drugs / Glutamine
Glutamine
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Other | Endari | sickle cell S-Lepore disease | 2021-06-15 | “We are looking forward to Swissmedic’s review of our MA application for Endari®” emmausmedical.com ↗ |
| Withdrawn | EU (EMA) | Xyndari | sickle cell S-Lepore disease | 2019-09-19 | “today announced the withdrawal of its marketing authorization application (MAA) to the European Medicines Agency (EMA) for Xyndari™ (glutamine) for the treatment of sickle cell disease.” emmausmedical.com ↗ |
| Refused (EMA) | EU (EMA) | Xyndari | sickle cell S-Lepore disease | 2019-05-30 | “the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion in relation to use of Xyndari™ (glutamine) in the...” emmausmedical.com ↗ |
Trials 42
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04388371 | Oct 2019 → Jun 2021 | lymphangioleiomyomatosis | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02351323 | May 2010 → Aug 2014 | type 2 diabetes mellitus | Boston Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00645879 | Jul 2008 → Aug 2009 | propionic acidemia | Nicola Longo | Completed | No outcome recorded |
| Phase 1 | NCT00178581 | Jun 2005 → Sep 2006 | — | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| Phase 1 | NCT00213551 | Apr 2004 → Jun 2008 | — | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 29 trials · 2 missed | ||||||
| Phase 2 | NCT07466758 | Oct 2024 → Mar 2026 | muscular atrophy | Biruni University | Completed | No outcome recorded |
| Phase 2 | NCT06617182 | Sep 2024 → Oct 2028 expected | enteritis | Yongquan Shi | Recruiting | No outcome recorded |
| Phase 2 | NCT01607879 | Mar 2014 → Jul 2018 | prostate cancer | Medical College of Wisconsin | Completed | Missed primary |
| Phase 2 | NCT01783522 | Feb → Nov 2013 | chemotherapy-induced toxicity, peripheral neuropathy, plasma cell myeloma | Beth Faiman | Terminated | No outcome recorded |
| Phase 2 | NCT01794884 | Jan 2013 → Mar 2014 | coronary artery disorder, rheumatic heart disease | Yuejiang Liu | Completed | No outcome recorded |
| Phase 2 | NCT00913692 | Jun 2009 → Dec 2011 | herpes labialis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00365768 | Oct 2004 → Jun 2012 | kidney cancer, leukemia, lymphoma, sarcoma +1 | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT00131508 | May 2004 → Apr 2009 | sickle cell disease | St. Jude Children's Research Hospital | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT00010634 | Sep 1999 → Jul 2004 | periodontitis | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT01263041 | May 2011 → Feb 2014 | infectious disease with sepsis, necrotizing enterocolitis | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT00016653 | Jun 2000 → Dec 2006 | Duchenne muscular dystrophy | Cooperative International Neuromuscular Research Group | Completed | Missed primary |
| Phase 311 trials · 2 missed | ||||||
| Phase 3 | NCT06031012 | Sep 2023 → Oct 2025 | mucositis | Air Force Military Medical University, China | Completed | No outcome recorded |
| Phase 3 | NCT05852990 | Mar 2022 → Dec 2026 expected | non-small cell lung carcinoma | National Cancer Institute of Mexico | Recruiting | No outcome recorded |
| Phase 3 | NCT04909905 | May → Oct 2021 | COVID-19 | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT03113240 | Apr → Oct 2017 | — | Shahid Beheshti University | Completed | No outcome recorded |
| Phase 3 | NCT01952847 | Jul 2014 → Mar 2021 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Terminated | Missed primary |
| Phase 3 | NCT01087658 | Feb 2010 → Mar 2013 | colorectal neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00455247 | Oct 2007 → Jan 2012 | digestive system cancer | Nestlé | Completed | No outcome recorded |
| Phase 3 | NCT00133406 | Jun 2006 → Dec 2011 | diarrheal disease | University of Virginia | Unknown | No outcome recorded |
| Phase 3 | NCT00195013 | Dec 2003 → May 2014 | breast cancer, peripheral neuropathy | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 3 | NCT00005775 | Jul 1999 → Dec 2000 | fetal growth restriction, neonatal sepsis | NICHD Neonatal Research Network | Completed | Missed primary |
| Phase 3 | NCT00018109 | — | Duchenne muscular dystrophy | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT03782155 | Jun → Aug 2021 | diabetes mellitus | Hospital General de Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT03867214 | Jan 2019 → Mar 2021 | mucositis, pneumonia | Yanzhao | Unknown | No outcome recorded |
| Phase 4 | NCT00204958 | Feb 2004 → May 2007 | bone marrow disorder, disease related to hematopoietic stem cell transplant | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT00922714 | Oct 2003 → May 2007 | — | Scandinavian Critical Care Trials Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase not applicable11 trials | ||||||
| — | NCT04693936 | Feb 2021 → Sep 2024 | Hashimoto thyroiditis, psoriasis | University of Crete | Unknown | No outcome recorded |
| — | NCT03917095 | May → Jun 2019 | ulcerative colitis | The Second Hospital of Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT04442633 | Apr → Aug 2019 | lichen planus | Hams Hamed Abdelrahman | Completed | No outcome recorded |
| — | NCT03199638 | Apr 2016 → Jun 2017 | type 1 diabetes mellitus | Nemours Children's Clinic | Completed | No outcome recorded |
| — | NCT01758783 | Jun 2012 → Jun 2013 | enteritis | Nanjing University School of Medicine | Unknown | No outcome recorded |
| — | NCT01576003 | Apr 2012 → Jun 2015 | infectious disease, short bowel syndrome | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| — | NCT01750138 | Jun 2011 → Jun 2014 | — | Scarborough General Hospital | Unknown | No outcome recorded |
| — | NCT01239680 | Jan 2011 → Nov 2013 | — | University of Missouri, Kansas City | Completed | No outcome recorded |
| — | NCT00334984 | Jan 2007 → ? | undifferentiated high grade pleomorphic sarcoma of bone | Children's Oncology Group | Withdrawn | No outcome recorded |
| — | NCT00563498 | Jul 2004 → Jun 2006 | hepatic veno-occlusive disease, mucositis, pulmonary venoocclusive disease | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
| — | NCT00005889 | Oct 1999 → ? | hyperglycemia | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| Comparator or background therapy16 trials | ||||||
| Phase 0 | NCT05569993 Comparator | Oct 2022 → Oct 2023 | traumatic brain injury | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05655819 Comparator | Feb 2023 → Dec 2025 | dyspepsia | David J. Cangemi | Completed | No outcome recorded |
| Phase 1/2 | NCT04507945 Background | Oct 2020 → Sep 2021 | bowel dysfunction | Nanjing University School of Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT02589145 Background | Jun 2016 → Apr 2019 | lymphoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02701673 Background | Jun 2016 → Jun 2019 | lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01983969 Background | Nov 2013 → Nov 2017 | cancer of unknown primary site, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT07053761 Comparator | Jun 2025 → Jun 2026 overdue | radiation proctitis | Peking University First Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02961816 Background | Jun 2017 → Jun 2021 | lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02114502 Background | Sep 2014 → Sep 2018 | plasma cell myeloma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02012608 Comparator | Jun 2014 → Apr 2019 | breast cancer | University of Arkansas | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01414244 Comparator | Nov 2010 → Dec 2015 | irritable bowel syndrome | Tulane University | Completed | No outcome recorded |
| Phase 2 | NCT00255229 Comparator | Dec 2002 → Jan 2010 | colorectal cancer | AHS Cancer Control Alberta | Completed | No outcome recorded |
| Phase 2/3 | NCT00318331 Comparator | May 2006 → Sep 2007 | critical illness polyneuropathy, infectious disease with sepsis, respiratory failure | Christiana Care Health Services | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT07287592 Comparator | Dec 2025 → Dec 2026 expected | cancer, peripheral neuropathy | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07442084 Comparator | Mar → Nov 2025 | polyp of large intestine | Xi'an Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT01704664 Comparator | Mar 2007 → Jul 2021 | gastric cancer | Medical University of Bialystok | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 38
| Date | Issuer | Release |
|---|---|---|
| 2025-06-26 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements emmausmedical.com ↗
The additional information provides a more comprehensive characterization of Endari, including confirmation of dosing by body weight, no unwanted accumulation through twice daily dosing, and the ability to administer Endari with or without food. |
| 2024-02-02 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico emmausmedical.com ↗ |
| 2023-07-13 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman emmausmedical.com ↗
today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari® (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older. |
| 2022-04-07 | Emmaus Medical, Inc. | Results Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology emmausmedical.com ↗
Furthermore, as compared to baseline, the number of blood transfusions at 24, 48 and 72 weeks was considerably lower (median, from 3.0 to 0.0;p<0.00001). |
| 2021-12-14 | Emmaus Medical, Inc. | Results Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting emmausmedical.com ↗ |
| 2021-10-26 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Submits Application for U.A.E. Marketing Authorization for Endari emmausmedical.com ↗
Emmaus Life Sciences, Inc. (OTC: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the submission of its application for marketing authorization of Endari® to the United Arab Emirates (U.A.E.) Ministry of Health. |
| 2021-08-17 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Announces Bahrain Temporary License of Endari emmausmedical.com ↗ |
| 2021-07-15 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Announces Submission of Endari Marketing Authorization Application in Kuwait emmausmedical.com ↗
We are pleased to announce the submission of our marketing authorization application to the Kuwaiti authorities. |
| 2021-06-15 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic emmausmedical.com ↗ |
| 2021-05-26 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari to the Saudi Food and Drug Authority emmausmedical.com ↗ |
| 2020-12-03 | Emmaus Medical, Inc. | Regulatory Endari® Granted Orphan Drug Status in Switzerland emmausmedical.com ↗
Torrance CA, December 3, 2020 - Emmaus Life Sciences, Inc. (OTC: EMMA) , a leader in the treatment of sickle cell disease, announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted orphan drug status to Endari®. |
| 2020-11-10 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari® emmausmedical.com ↗
announced today that it has submitted a temporary license application for Endari® to the National Health Regulatory Authority in the Kingdom of Bahrain. |
| 2020-11-03 | Emmaus Medical, Inc. | Regulatory FDA Approves Updated Label for Endari® emmausmedical.com ↗
Based on approval from the FDA, the updated label includes a statement that the clinical benefit of Endari® was observed irrespective of hydroxyurea usage and a new step-by-step instruction for use section at the end of the prescribing information. |
| 2020-08-18 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority emmausmedical.com ↗ |
| 2020-08-05 | Emmaus Medical, Inc. | Results Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial emmausmedical.com ↗
We are pleased to provide this remarkable topline data where we observed consistent improvement in the study patients. |
| 2020-06-29 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli Ministry of Health emmausmedical.com ↗
Endari® is approved in Israel as in the U.S. as an amino acid indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. |
| 2020-04-27 | Emmaus Medical, Inc. | Results APCER Report Confirms Endari ® Safety emmausmedical.com ↗ |
| 2020-04-16 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Announces SFDA (Saudi Food & Drug Authority) Accepts Endari® Priority Review Request emmausmedical.com ↗ |
| 2020-01-29 | Emmaus Medical, Inc. | Results Emmaus Life Sciences Reports Positive Top-Line Preliminary Results in First Patient in Diverticulosis Pilot Trial emmausmedical.com ↗
“A marginal but decreased size in some of the diverticula compared to the baseline.” |
| 2019-09-24 | Emmaus Medical, Inc. | Results Emmaus Life Sciences Reinforces Positive Outcomes of Endari® Clinical Trials, Including Efficacy Findings That Led to FDA Approval emmausmedical.com ↗
The results of the Phase 3 study clearly demonstrated the efficacy of Endari ® in both the primary and secondary endpoints. |
| 2019-09-19 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Announces Withdrawal of Marketing Authorization Application to European Medicines Agency emmausmedical.com ↗
Emmaus Life Sciences, Inc. (OTC: EMMA) , a leader in sickle cell disease treatment, today announced the withdrawal of its marketing authorization application (MAA) to the European Medicines Agency (EMA) for Xyndari™ (glutamine) for the treatment of sickle cell disease. |
| 2019-05-30 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Announces New CFO and EMA Opinion emmausmedical.com ↗
Separately, the company also announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion in relation to use of Xyndari™ (glutamine) in the treatment of sickle cell disease (SCD). |
| 2018-11-02 | Emmaus Medical, Inc. | Results Emmaus Life Sciences Announces Presentation of Abstract at the 2018 American Society of Hematology Annual Meeting emmausmedical.com ↗
The ASH abstract shows consistent benefit to those patients in the Endari treatment arm, irrespective of their history of sickle cell crises prior to their participation in the trial. |
| 2018-07-18 | Emmaus Medical, Inc. | Results Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease emmausmedical.com ↗
Results showed a significant improvement in these measures: lower median number of sickle cell crises, fewer hospitalizations, lower cumulative days in hospital, and lower incidence of acute chest syndrome |
| 2018-07-11 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Announces FDA Acceptance of IND Application for Clinical Study of L-glutamine for Treatment of Diverticulosis emmausmedical.com ↗
today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for L-glutamine as a treatment for diverticulosis. |
| 2018-03-12 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for Sickle Cell Disease Treatment Xyndari (oral glutamine) emmausmedical.com ↗
Emmaus Life Sciences, Inc. (Emmaus) announced today that the company’s Marketing Authorization Application (MAA) for Xyndari has been fully validated and is now under assessment by the European Medicines Agency (EMA) for the treatment of sickle cell disease. |
| 2017-12-21 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency emmausmedical.com ↗
Emmaus Life Sciences announced today that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the company's pediatric investigation plan (PIP) for its treatment of sickle cell disease. |
| 2017-11-28 | Emmaus Medical, Inc. | Results Emmaus Life Sciences, Inc. to Present Results of Phase 3 Study of EndariTM (L-glutamine oral powder) at 59th American Society of Hematology Annual Meeting emmausmedical.com ↗
The results to be presented demonstrated that the average cumulative crisis count was reduced by approximately 25% over the 48-week study. |
| 2017-07-07 | Emmaus Medical, Inc. | Regulatory The U.S. Food & Drug Administration Approves Endari™ (L-glutamine oral powder), the First and Only Treatment for Sickle Cell Disease in Pediatric Patients and First in Nearly 20 Years for Adults emmausmedical.com ↗ |
| 2017-05-24 | Emmaus Medical, Inc. | Regulatory FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell Disease emmausmedical.com ↗
Emmaus Life Sciences Inc. announced today that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of EndariTM for the treatment of sickle cell disease (SCD) is favorable. |
| 2016-11-30 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Receives Notice of FDA PDUFA Date for Investigational L-glutamine Treatment for Sickle Cell Disease emmausmedical.com ↗
“Notification of the PDUFA date brings us one step closer to providing healthcare providers and patients with a new treatment option for sickle cell disease,” said Yutaka Niihara, MD, MPH, Chairman and Chief Executive Officer of Emmaus Life Sciences. |
| 2016-11-08 | Emmaus Medical, Inc. | Regulatory Emmaus’ New Drug Application for Sickle Cell Disease Accepted for Review by FDA emmausmedical.com ↗
Emmaus Life Sciences, Inc., announced today that the Food and Drug Administration (FDA) has accepted for review the New Drug Application for its orally administered pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell disease. |
| 2016-09-08 | Emmaus Medical, Inc. | Regulatory Emmaus Life Sciences Submits New Drug Application for Sickle Cell Disease Treatment emmausmedical.com ↗ |
| 2015-12-02 | Emmaus Medical, Inc. | Results Emmaus Life Sciences to Present Additional New Data from its Phase 3 Sickle Cell Disease Trial at 57th Annual ASH Meeting emmausmedical.com ↗
Additional analyses on the data from the Company’s Phase 3 trial demonstrated a reduction in severity of painful crisis. |
| 2015-03-31 | Emmaus Medical, Inc. | Results Emmaus Life Sciences to Present Phase 3 Sickle Cell Disease Clinical Trial Data emmausmedical.com ↗ |
| 2015-02-02 | Emmaus Medical, Inc. | Results Emmaus Life Sciences Phase 3 Sickle Cell Disease Trial Data Included in 2015 Highlights of ASH program emmausmedical.com ↗
Study participants were randomized to receive daily PGLG (152 patients) or placebo (78 patients) for 48 weeks, after which treatment levels were tapered to zero. |
| 2012-07-17 | Emmaus Medical, Inc. | Regulatory European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical’s Sickle Cell Treatment emmausmedical.com ↗
Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company’s investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease. |
| 2012-05-29 | Emmaus Medical, Inc. | Regulatory Emmaus Medical’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Status from European Medicines Agency emmausmedical.com ↗
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). |
All press releases naming this drug 49 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 58 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glutamine | “The intervention includes a personalised pharmaconutrition formula containing arginine, glutamine, and beta-hydroxy-beta-methylbutyrate (HMB).” NCT07466758 ↗57“the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment.” NCT04507945 ↗ “Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.” NCT03113240 ↗ “Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day” NCT04693936 ↗ “Drug: Glutamine” NCT01263041 ↗ |
| Known as | AES-14 | “Compare the efficacy of a new preparation of glutamine (AES-14) vs placebo in reducing the incidence of grade 3 or 4 chemotherapy-induced oral mucositis during the first course...” NCT00334984 ↗ |
| Known as | Dipeptiven | “Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag.” NCT01704664 ↗ |
| Known as | L-Glutamin \&Chios Mastiha | “Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day” NCT04693936 ↗ |
| Known as | L-Glutamine | “The aim of this study is to investigate the effect of parenteral L-Glutamine supplementation added to enteral nutrition on short-term ICU mortality (7 days) in Covid-19...” NCT04909905 ↗ |
| Modality | Other / unclassified | “Glutamine is considered a conditionally essential amino acid during critical illness.” NCT00178581 ↗ |
| Route | Intravenous | “glutamine or alanine IV over the last 5 hours” NCT00005889 ↗ |